Flow Cytometric Evaluation of Treatment Responses in Sic

Sic 治疗反应的流式细胞术评估

• 批准号: 7332597
• 负责人: irina maric
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7332597
• 关键词: Flow; Cytometric; Evaluation; Treatment; Responses

Flow cytometric analysis of red blood cells is used to monitor levels of Hemoglobin F (HbF) and Hemoglobin F-containing reticulocytes (F-cells) in sickle cell disease (SCD) patients and to assess their responses to different treatments. Lately, erythropoietin is being used more widely in the management of sickle cell disease, often in conjunction with hydroxyurea (HU). We have followed for a median of 11 months patients with sickle syndromes that were treated with erythropoietin or darbepoietin (both referred to as EPO). The median age of sickle syndrome patients was 51 (24 to 70) years; most patients had sickle-associated pulmonary hypertension. There was three study groups: (1) patients with pulmonary hypertension that were given EPO for reticulocytopenia on HU, (2) patients with pulmonary hypertension and renal insufficiency that were given EPO and HU concurrently, and (3) patients treated with EPO for miscellaneous reasons. Results show that the percent of HbF and F-cells rose in all evaluable patients. Results suggest that EPO therapy may allow more aggressive HU dosing in high-risk SCD patients and in the setting of mild renal insufficiency, common to the aging sickle cell population. EPO appears to be safe in SCD, particularly when used in conjunction with HU. One paper is published.

红细胞的流式细胞仪分析用于监测镰状细胞病（SCD）患者中含有血红蛋白F（HBF）和血红蛋白F的网状细胞（F细胞）的水平，并评估其对不同治疗的反应。 最近，红细胞生成素通常与羟基脲（HU）结合使用。我们遵循了11个月的镰状综合征患者的中位数，这些患者接受了促红细胞生成素或darbepoietin治疗（都称为EPO）。镰状综合征患者的中位年龄为51（24至70）年；大多数患者患有镰状肺动脉高压。有三个研究组：（1）患有肺高血压的患者在HU上接受EPO的网状细胞减少症，（2）患有肺动脉高压和肾功能不全的患者同时给予EPO和HU，以及（3）出于杂项原因用EPO治疗的患者。 结果表明，所有可评估患者的HBF和F细胞百分比上升。结果表明，EPO疗法可以在高危SCD患者中允许更具侵略性的HU剂量，并在衰老的镰状细胞种群常见的轻度肾功能不全的情况下。 EPO在SCD中似乎是安全的，尤其是与HU结合使用时。发表一篇论文。